BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary

Status Recruiting

Clinical Trial Summary

Stress urinary incontinence (SUI) is a condition that affects both men and women. SUI is the involuntary leakage of urine caused by an increase in intra-abdominal pressure from activities such as exercise, coughing, laughing, or sneezing. It can significantly affect quality of life as patients avoid activities or behaviors that cause leakage. This clinical trial will compare the efficacy of the Emsella chair to sham and determine if electromagnetic technology is effective in the treatment of SUI.

Clinical Trial Description

This is a prospective, sham-controlled, observational study of subjects undergoing electromagnetic perineal stimulation for the treatment of SUI. Eligible subjects will be randomized to receive active treatment or sham in a 1:1 ratio. Eight treatments (2 treatments each week) for 4 weeks will be completed with the Emsella chair to the pelvic floor muscles. Electromagnetic stimulation of the pelvic floor is a FDA approved therapy whereby a coil generates pulsed electromagnetic fields that penetrate deep into the pelvic floor muscles inducing stimulation and providing rehabilitation of weak pelvic muscles.The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.This technology is typically not covered by insurance, is minimally invasive, and safe, but has limited data available. Currently, there is no data available from sham controlled studies evaluating efficacy of this technology. The purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of SUI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04133675
Study type	Interventional
Source	William Beaumont Hospitals
Contact	Erica Zagaja, RN
Phone	248-551-0642
Email	Erica.Zagaja@beaumont.org
Status	Recruiting
Phase	N/A
Start date	December 18, 2019
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04829357` - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed	`NCT05493735` - Lidocaine for Pessary Check Pain Reduction	Phase 3
Completed	`NCT04512053` - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence	Phase 2
Active, not recruiting	`NCT06224335` - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting	`NCT05304312` - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women	N/A
Not yet recruiting	`NCT05527665` - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting	`NCT04558762` - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn	`NCT02524366` - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement	N/A
Completed	`NCT01924728` - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence	N/A
Completed	`NCT01676662` - Solace European Confirmatory Trial	N/A
Unknown status	`NCT01455779` - Lyrette: Renewing Continence Objective and Subjective Efficacy Study	N/A
Terminated	`NCT01029106` - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)	N/A
Completed	`NCT01123096` - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?	N/A
Completed	`NCT01770691` - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence	N/A
Withdrawn	`NCT00573703` - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence	Phase 4
Completed	`NCT00234754` - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women	N/A
Completed	`NCT00441454` - Retropubic vs. Transobturator Tension-free Vaginal Tape	N/A
Completed	`NCT03985345` - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence.	N/A
Active, not recruiting	`NCT03671694` - Laser Vaginal Treatment for SUI	N/A
Completed	`NCT04097288` - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms